Industry News
Pharmaceutical Industry News
In the latest in a string of…
In the latest in a string of setbacks in biopharma’s efforts to fight Medicare drug price negotiations, a lawsuit from the industry’s top lobbying group has been rejected at the appeals level.
Amgen and AstraZeneca’s…
Amgen and AstraZeneca’s inflammatory disease drug Tezspire has clinched a phase 3 win in eosinophilic esophagitis as the partners eye another challenge to Sanofi and Regeneron’s incumbent Dupixent.
Labcorp’s Catie Schlechter…
Labcorp's Catie Schlechter discusses how sponsors are using real-world data to improve trial design, recruitment and strategy.
New Drug Approved by F.D.A. for Pancreatic Cancer Could Be First of Many
Companies are testing dozens of similar drugs in cancers of the pancreas, lung, colon and more.
Artis BioSolutions opened the…
Artis BioSolutions opened the doors to a new manufacturing center located in Bilbao, Spain, that expands the CDMO’s production capabilities in next-generation genetic medicines.
The Trump administration will…
The Trump administration will soon unveil most favored nation drug pricing deals with several mid-sized biopharma companies, according to a report from Bloomberg. The announcement is expected on Monday.
Since its immunology scholarship…
Since its immunology scholarship was established in 2016, AbbVie has supported more than 350 students living with immunology conditions, with its investments in the program totaling more than $6 million.
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.
As AI reshapes health discovery,…
As AI reshapes health discovery, GoodRx is helping pharma turn consumer and HCP questions into action.
Some 20 years after helping…
Some 20 years after helping introduce the first once-daily single-tablet HIV regimen, Gilead Sciences has crossed the regulatory finish line with a new oral treatment option in the U.S.
Following dynamite data that…
Following dynamite data that earned a standing ovation at the American Society of Clinical Oncology meeting in May, Revolution Medicines’ Ras inhibitor daraxonrasib has been approved by the FDA for the treatment of metastatic pancreatic
Fresh off a phase 3 win in biliary…
Fresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody ivonescimab’s ability beyond non-small cell lung cancer, even as she continues to defend the
Baxter has initiated a recall of…
Baxter has initiated a recall of two products because of particulate matter and Vitruvias Therapeutics has recalled one lot of thyroid tablets because of their potential to be “superpotent."
Endemic media and broad reach each…
Endemic media and broad reach each do half the job. What makes them work together is not more spend, but a signal that says when.
As the leadership vacuum at the…
As the leadership vacuum at the top of the FDA looks poised to close with President Donald Trump’s nominee pick for a replacement commissioner, the agency is reportedly weighing whether to add two new deputy
Teva is increasingly highlighting…
Teva is increasingly highlighting its innovative drug bona fides these days, seeking to style itself as both a novel drug-producing biopharma and a generics powerhouse.
Bausch + Lomb has come up short in…
Bausch + Lomb has come up short in a phase 2 trial, testing its combination of dry-eye disease drugs Xiidra and Miebo. While the study missed its primary endpoint, the Ontario eye care specialist has
The healthcare conglomerate ,which…
The healthcare conglomerate ,which ranks eighth on the Fortune 500 list, is set to envelope privately held Precision Medicine Group into its oncology branch as part of an ongoing effort to grow it's high-margin cancer
Millions of HCPs follow digital…
Millions of HCPs follow digital opinion leaders online. Here's how pharma can find, vet, and support the right ones in 2026.
Sixteen months after Johnson &…
Sixteen months after Johnson & Johnson scored its initial FDA approval for Imaavy, the pharma giant has tacked on a label expansion for the monoclonal antibody. The U.S. regulator has signed off on Imaavy to